| Literature DB >> 30323274 |
Richard Newton1,2, Alice Rouleau3, Anna-Greta Nylander4, Jean-Yves Loze5, Henrike K Resemann6, Sara Steeves6, Benedicto Crespo-Facorro7.
Abstract
Schizophrenia is a debilitating psychiatric disorder and patients experience significant comorbidity, especially cognitive and psychosocial deficits, already at the onset of disease. Previous research suggests that treatment during the earlier stages of disease reduces disease burden, and that a longer time of untreated psychosis has a negative impact on treatment outcomes. A targeted literature review was conducted to gain insight into the definitions currently used to describe patients with a recent diagnosis of schizophrenia in the early course of disease ('early' schizophrenia). A total of 483 relevant English-language publications of clinical guidelines and studies were identified for inclusion after searches of MEDLINE, MEDLINE In-Process, relevant clinical trial databases and Google for records published between January 2005 and October 2015. The extracted data revealed a wide variety of terminology and definitions used to describe patients with 'early' or 'recent-onset' schizophrenia, with no apparent consensus. The most commonly used criteria to define patients with early schizophrenia included experience of their first episode of schizophrenia or disease duration of less than 1, 2 or 5 years. These varied definitions likely result in substantial disparities of patient populations between studies and variable population heterogeneity. Better agreement on the definition of early schizophrenia could aid interpretation and comparison of studies in this patient population and consensus on definitions should allow for better identification and management of schizophrenia patients in the early course of their disease.Entities:
Year: 2018 PMID: 30323274 PMCID: PMC6189105 DOI: 10.1038/s41537-018-0063-7
Source DB: PubMed Journal: NPJ Schizophr ISSN: 2334-265X
Summary of primary studies identified in the review
| Region | Number of studies | Total number of participants | Publication years |
|---|---|---|---|
| North America | 66 | 6722 | 2005–2015 |
| Europe | 177 | 37,180 | 2005–2015 |
| Australia | 19 | 1484 | 2005–2015 |
| Othera | 204 | 30,372 | 2005–2015 |
a Other regions included Asia (n = 175), Middle East (n = 10), Central/South America (n = 8), Africa (n = 3) or encompassed multiple regions (n = 8)
Fig. 1Summary of definitions used in primary studies (N = 466) identified in the literature review
Fig. 2Proportion of studies (N = 466) using single vs overlapping early schizophrenia definitions; stratified by a study location and b design
Fig. 3Distribution of cut-offs used with duration-based criteria, stratified by disease onset definition (n). Footnote: studies with multiple definitions were repeated under each category (n = 5)
Rationale provided in primary studies for the selection of patients with disease duration under a particular threshold
| Rationale based on prior experience and evidence | Rationale linked to study methodology |
|---|---|
| Prior evidence for the time at which schizophrenia reaches a plateau during the first 5 years[ | Duration period reduced to minimise confounding due to variation in disease duration and time on antipsychotic therapy[ |
| The majority of the deterioration in psychosocial functioning occurs within the first 3 years[ | Duration period extended to increase the number of eligible participants[ |
| Most functional disability occurs within the first 5 years of the disease[ | Duration period chosen to maintain consistency with another trial[ |
| Minimum duration of follow-up for first-episode studies should be 2 years[ | |
| Patients with adolescent onset of schizophrenia and duration less than 3 years are believed to be in a ‘critical period’[ | |
| Progression of the disease might occur predominantly in the first 5 years[ |